Introduction and Objective: GLP-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) are guideline-recommended therapies that reduce cardiovascular and renal risk in adults with type 2 diabetes (T2D). Uptake varies by socioeconomic factors. We examined socioeconomic differences in use among eligible U.S. adults with T2D. Methods: We pooled 2018-2020 and 2021-2023 Medical Expenditure Panel Survey data to identify adults with T2D and determine eligibility using American Diabetes Association criteria. Eligibility included having atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk for GLP-1 RA or SGLT2i use, or having heart failure or chronic kidney disease for SGLT2i use. Weighted analyses estimated overall and subgroup use by race/ethnicity, income, insurance status, and region. Logistic regression assessed associations between use with socioeconomic, and clinical features. Results: About three-quarters of U.S. adults with T2D met at least one eligibility criterion in both periods. Among eligible adults, use of GLP-1 RA or SGLT2i increased from 12.3% to 26.5%. Use was lower among racial and ethnic minority groups and uninsured or publicly insured adults, and highest among adults with incomes ≥400% of the federal poverty level. Conclusion: Despite broad eligibility, substantial socioeconomic disparities persist in use of GLP-1 RAs and SGLT2 inhibitors, stressing the need to improve equitable access. Disclosure Y. Wang: None. K. Bullard: None. R. Li: None. O. Idubor: None. P. Zhang: None.
WANG et al. (Fri,) studied this question.